Increased Risk of Hypertension in Low aged-carriers with rs2596542 Risk-allele

Document Type : Original Article


1 Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran.

2 Assistant Professor, Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran

3 Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran


Background:Hypertension with its related disorders is one of the most common health problems among the Iranian population. Hypertension can be developed by chronic stress and a positive association between stress and rs2596542 has been confirmed.
Methods:A Total number of 112 hypertensive patients and 97 healthy individuals were involved in the study. Total blood genomic-DNA was extracted and PASA (PCR amplification of specific alleles) method was used to amplify MICA-rs2596542 polymorphic site. Different genotypes were visualized. The normality of the data was assessed and the binary logistic regression was used for OR and 95%CI calculations.
Results:A-risk allele of rs2596542 increased the risk of hypertension development significantly (OR=1.734, p=0.006). Females were significantly more potent to hypertension development than males (OR=2.015, p=0.013). Risk-allele homozygotes (AA) showed a higher risk of hypertension development than GG (OR=2.132, p=0.020) and AG individuals (OR=3.206, p=0.006). Age adjustments at 70 years old, further increased the risk of hypertension development in GG (OR=3.772, p=0.011) and AG (OR=6.531, p=0.009) individuals.
Conclusion:A-risk allele of rs2596542 could increase the risk of hypertension up to 3.2 folds and this risk could be upraised after sex and age adjustments.


  1. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm hg, 1990-2015. JAMA 2017; 317(2):165-82.
  2. Mirzaei M, Moayedallaie S, Jabbari L, Mohammadi M. Prevalence of hypertension in Iran 1980–2012: a systematic review. J Tehran Heart Cent 2016; 11(4):159-67.
  3. Carson AP, Howard G, Burke GL, Shea S, Levitan EB, Muntner P. Ethnic differences in hypertension incidence among middle-aged and older U. S. adults: the multi-ethnic study of atherosclerosis. Hypertension 2011; 57(6):1101-7.
  4. Lackland DT. Racial differences in hypertension: implications for high blood pressure management. Am J Med Sci 2014; 348(2):135-8.
  5. Beevers G, Lip GY, O'Brien E. ABC of hypertension: The pathophysiology of hypertension. BMJ 2001; 322(7291):912-6.
  6. Justice AE, Howard AG, Chittoor G, Fernandez-Rhodes L, Graff M, Voruganti VS, et al. Genome-wide association of trajectories of systolic blood pressure change. BMC Proc 2016; 10(Suppl 7):321-7.
  7. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009; 41(6):677-87.
  8. Wain LV, Vaez A, Jansen R, Joehanes R, van der Most PJ, Erzurumluoglu AM, et al. Novel blood pressure locus and gene discovery using genome-wide association study and expression data sets from blood and the kidney. Hypertension 2017.
  9. Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat Genet 2017; 49(3):403-15.
  10. Ghadially H, Brown L, Lloyd C, Lewis L, Lewis A, Dillon J, et al. MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue. Br J Cancer 2017; 116(9):1208-17.
  11. Leelayuwat C, Townend DC, Degli-Esposti MA, Abraham LJ, Dawkins RL. A new polymorphic and multicopy MHC gene family related to nonmammalian class I. Immunogenetics 1994; 40(5):339-51.
  12. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998; 279(5357):1737-40.
  13. Schrambach S, Ardizzone M, Leymarie V, Sibilia J, Bahram S. In vivo expression pattern of MICA and MICB and Its relevance to auto-immunity and cancer. PLoS One 2007; 2(6):e518.
  14. Vallian S, Rad MJ, Tavallaei M, Tavassoli M. Correlation of major histocompatibility complex class I related A (MICA) polymorphism with the risk of developing breast cancer. Med Oncol 2012; 29(1):5-9.
  15. Spruill TM. Chronic psychosocial stress and hypertension. Curr Hypertens Rep 2010; 12(1):10-6.
  16. Augello G, Balasus D, Fusilli C, Mazza T, Emma MR, Giannitrapani L, et al. Association between MICA gene variants and the risk of hepatitis c virus-induced hepatocellular cancer in a sicilian population sample. OMICS 2018; 22(4):274-82.
  17. Lo PH, Urabe Y, Kumar V, Tanikawa C, Koike K, Kato N, et al. Identification of a functional variant in the MICA promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk. PLoS One 2013; 8(4):e61279.
  18. Mohamed AA, Elsaid OM, Amer EA, Elosaily HH, Sleem MI, Gerges SS, et al. Clinical significance of SNP (rs2596542) in histocompatibility complex class I-related gene A promoter region among hepatitis C virus related hepatocellular carcinoma cases. J Adv Res 2017; 8(4):343-9.
  19. Marangon CG, de Bitencorte JT, Michita RT, Lunge VR, Dos Santos DC, Álvares-da-Silva MR, et al. Association between MICA rs2596542 Polymorphism with the risk of hepatocellular carcinoma in chronic hepatitis C patients. Pathol Oncol Res 2020; 26(3):1519-25.
  20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16(3):1215.
  21. Erickson SR, Kornexl K. Blood pressure screening, control, and treatment for patients with developmental disabilities in general medicine practices. J Pharm Technol 2016; 32(6):234-9.
  22. Margolis KL, Palermo L, Vittinghoff E, Evans GW, Atkinson HH, Hamilton BP, et al. Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial. J Gen Intern Med 2014; 29(12):1599-606.
  23. Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study. Scientific Reports 2018; 8(1):9418.
  24. Buford TW. Hypertension and aging. Ageing Res Rev 2016; 26:96-111.
  25. Ehret GB, Caulfield MJ. Genes for blood pressure: an opportunity to understand hypertension. Eur Heart J 2013; 34(13):951-61.
  26. Manosroi W, Williams G. Genetics of Human Primary Hypertension: Focus on Hormonal Mechanisms. Endocrine Reviews 2018; 40(3):825-56.
  27. Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical renin-angiotensin system in kidney physiology. Compr Physiol 2014; 4(3):1201-28.
  28. Pojoga LH, Underwood PC, Goodarzi MO, Williams JS, Adler GK, Jeunemaitre X, et al. Variants of the Caveolin-1 Gene: A Translational Investigation Linking Insulin Resistance and Hypertension. J Clin Endocrinol Metab 2011; 96(8):E1288-92.
  29. Yamada Y, Ando F, Shimokata H. Association of gene polymorphisms with blood pressure and the prevalence of hypertension in community-dwelling Japanese individuals. Int J Mol Med 2007; 19(4):675-83.
  30. Grilo A, Fernandez ML, Beltrán M, Ramirez-Lorca R, González MA, Royo JL, et al. Genetic analysis of CAV1 gene in hypertension and metabolic syndrome. Thromb Haemost 2006; 95(4):696-701.
  31. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001; 104(3):342-5.
  32. Tabei SM, Nariman A, Daliri K, Roozbeh J, Khezri A, Goodarzi HR, et al. Simple renal cysts and hypertension are associated with angiotensinogen (AGT) gene variant in Shiraz population (Iran). J Renin Angiotensin Aldosterone Syst 2013; 16(2):409-14.
  33. Bonfim-Silva R, Guimarães LO, Santos JS, Pereira JF, Barbosa AA, Rios DL. Case-control association study of polymorphisms in the angiotensinogen and angiotensin-converting enzyme genes and coronary artery disease and systemic artery hypertension in African- and Caucasian-Brazilians. Journal of Genetics 2016; 95(1):63-9.
  34. Tsezou A, Karayannis G, Giannatou E, Papanikolaou V, Triposkiadis F. Association of renin-angiotensin system and natriuretic peptide receptor A gene polymorphisms with hypertension in a Hellenic population. J Renin Angiotensin Aldosterone Syst 2008; 9(4):202-7.
  35. Purkait P, Halder K, Thakur S, Ghosh Roy A, Raychaudhuri P, Bhattacharya S, et al. Association of angiotensinogen gene SNPs and haplotypes with risk of hypertension in eastern Indian population. Clin Hypertens 2017; 23:12.
  36. Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, et al. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens 2004; 17(1):8-13.
  37. Yu H, Lin S, Zhong J, He M, Jin L, Zhang Y, et al. A core promoter variant of angiotensinogen gene and interindividual variation in response to angiotensin-converting enzyme inhibitors. J Renin Angiotensin Aldosterone Syst 2014; 15(4):540-6.
  38. Mansego ML, Redon J, Marín R, González-Albert V, Martin-Escudero JC, Fabia MJ, et al. Renin polymorphisms and haplotypes are associated with blood pressure levels and hypertension risk in postmenopausal women. J Hypertens 2008; 26(2):230-7.
  39. Park J, Song K, Jang Y, Yoon SK. A polymorphism of the renin gene rs6682082 is associated with essential hypertension risk and blood pressure levels in Korean women. Yonsei Med J 2015; 56(1):227-34.
  40. Goto K, Kato N. MICA SNPs and the NKG2D system in virus-induced HCC. J Gastroenterol 2015; 50(3):261-72.
  41. Sharkawy RE, Bayoumi A, Metwally M, Mangia A, Berg T, Romero-Gomez M, et al. A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms. Scientific Reports 2019; 9(1):1439.
  42. Kumar V, Yi Lo PH, Sawai H, Kato N, Takahashi A, Deng Z, et al. Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma. PLoS One 2012; 7(9):e44743.
  43. Shi J, Szmania S, Zhan F, Shaughnessy J, Barlogie B, Tricot G, et al. Soluble and membrane bound MICA in myeloma do not adversely effect regulation of natural killer cell function via NKG2D. Blood 2004; 104(11):2462.
  44. Caillat-Zucman S. How NKG2D ligands trigger autoimmunity? Hum Immunol 2006; 67(3):204-7.
  45. Choy MK, Phipps ME. MICA polymorphism: biology and importance in immunity and disease. Trends Mol Med 2010; 16(3):97-106.
  46. Sharkawy RE, Bayoumi A, Metwally M, Mangia A, Berg T, Romero-Gomez M, et al. A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-beta1 dependent mechanisms. Sci Rep 2019; 9(1):1439.
  47. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 2004; 64(20):7596-603.
  48. Siegel PM, Massagué J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 2003; 3(11):807-21.
  49. Walshe TE, Saint-Geniez M, Maharaj AS, Sekiyama E, Maldonado AE, D'Amore PA. TGF-beta is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS One 2009; 4(4):e5149.
  50. Xia M, Guerra N, Sukhova GK, Yang K, Miller CK, Shi GP, et al. Immune activation resulting from NKG2D/ligand interaction promotes atherosclerosis. Circulation 2011; 124(25):2933-43.